StartGNV Hosts Women in Innovation AMA
StartGNV hosted a live ‘Ask me Anything’ on Thursday, March 25, 2021, to highlight women in Gainesville innovation. The three panelists were UF Innovate | The Hub resident clients Helena Cowley, president and CEO of Oxidien Pharmaceuticals; Victoria Liu, founder of Byppo; and our very own Jennifer Harrell, interim assistant director of UF Innovate | The Hub.
Oxidien Pharmaceuticals Announce Additions to New Strategic Advisory Board
UF Innovate | The Hub resident client Oxidien Pharmaceuticals announced two additions to its newly organized Strategic Advisory Board (SAB).
Arranta Bio Named Honoree in GrowFL Companies to Watch
Arranta Bio is pleased to be among the top 50 second-stage companies in Florida selected as honorees in the 2020 GrowFL Florida Companies to Watch, a statewide competition that identifies companies expected to see significant growth over the next several years. The 2020 GrowFL Florida Companies to Watch awards celebration is brought to you by […]
Oxidien Pharmaceuticals Selected as Winner of Buzz of BIO in Early Stage Entrepreneur Category
UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company mitigating kidney stone disease by treating secondary hyperoxaluria, announced that it was recognized as a winner in Buzz of BIO, in the Early Stage Entrepreneur category following a nomination and extensive voter participation. Helena Cowley, CEO of Oxidien Pharmaceuticals said, “We are grateful for everyone’s […]
Oxidien Announces Publication of Clinical Results Demonstrating Significant Reduction in Urinary Oxalate
UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company mitigating kidney stone disease by treating secondary hyperoxaluria, announced the publication of data from a clinical study on the effectiveness of its highly potent and acid-stable Oxalate Decarboxylase (OxDC) to reduce urinary oxalate in subjects on a high oxalate diet. The study was […]
Oxidien Pharmaceuticals Announce Addition to Scientific and Medical Advisory Board
UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, announced three additions to its Scientific and Medical Advisory Board (SMAB) to provide external advice on its development activities and clinical program in secondary hyperoxaluria. Helena Cowley, CEO of Oxidien, said “The […]
Selecting a Microbiome CDMO Partner for the Long Term, Arranta Bio Shares
As more microbiome-based therapies progress through the clinic toward approval for market launch, concerns over the lack of outsourcing capacity for process development and commercial manufacturing of live biotherapeutic products are increasing. Arranta Bio is investing heavily in both its process development and cGMP manufacturing capabilities for the supply of clinical trial material and in […]
Oxidien Pharmaceuticals Receives High Recognition at RESI Conference in Partnership With Women in Bio
UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company mitigating kidney disease by treating secondary hyperoxaluria, announced that its compelling investment opportunity was recognized by conference attendees casting their votes for the company in the Innovation Challenge. The votes cast for Oxidien placed the company in the top three in the impressive […]
Oxidien Among Top Three Winners of Digital RESI June Innovation Challenge
The 3-day Digital RESI June conference announced the Top 3 Winners of the Innovation Challenge. UF Innovate | The Hub resident client Oxidien Pharmaceuticals was among the winners. Watch Oxidien’s virtual poster, short pitch, and other supplementary materials here. Oxidien Pharmaceuticals is a clinical-stage drug development company developing a treatment for enteric hyperoxaluria, a large unmet need in […]
Arranta Bio Announces Completion of Its Microbiome Process Development Laboratory Expansion and Commitment to Additional Early Clinical GMP Capacity
Arranta Bio, the leading microbiome contract development and manufacturing organization (CDMO), announced the completion of its process development laboratory expansion project and a commitment to add additional early-clinical GMP capacity at its Center of Excellence for Microbiome Process Development and Early Clinical Supply. Arranta has completed the expansion of purpose-built microbiome process development laboratories in […]